HAYWARD, CA, Aarvik Therapeutics, announced it has successfully closed a Series Seed 2 financing round.
Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it has successfully closed a Series Seed 2 financing round.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
